GeneDx Holdings (WGS)
NASDAQ:WGS
Want to see WGS full AI Analyst Report?
WGS Stock Chart & Stats
$65.96
-$4.29(-4.42%)
At close: 4:00 PM EST
$65.96
-$4.29(-4.42%)
Day’s Range― - ―
52-Week Range$32.21 - $170.87
Previous CloseN/A
Volume338.68K
Average Volume (3M)666.82K
Market Cap
$1.17B
Enterprise Value$1.28B
Total Cash (Recent Filing)$170.69M
Total Debt (Recent Filing)$168.19M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding29,688,026
10 Day Avg. Volume649,621
30 Day Avg. Volume666,818
Financial Highlights & Ratios
PEG Ratio2.67
Price to Book (P/B)11.35
Price to Sales (P/S)8.18
P/FCF Ratio245.23
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue2.90
Enterprise Value/Gross Profit4.25
Enterprise Value/Ebitda-102.40
Forecast
1Y Price Target
$91.25Price Target Upside38.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.13
Revenue Forecast (FY)$487.66M
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionSignificant expansion of the sales force targeting pediatric, prenatal, neonatal and international markets could accelerate adoption and drive revenue growth as more clinicians begin ordering the company's tests.
Product Mix And PricingConversion from panel-based tests to whole exome and whole genome testing, combined with recent strength in average selling prices, supports a runway for higher testing volumes and improved revenue per test.
Profitability OutlookCompany guidance for positive adjusted net income and sustained healthy gross margins signals potential improvement in profitability that can reassure investors about long-term financial sustainability.
Bears Say
Cost PressureElevated expenses tied to sizable investments to pursue larger market opportunities pose a risk to near-term profitability and could weigh on investor sentiment if revenue ramps slower than planned.
Execution RiskScaling into new markets and deploying a much larger sales team may delay revenue realization because market entry and operational ramp-up often take time to produce consistent test volumes.
Payer And Volume RiskDeclines in hereditary testing volumes and uncertainty around payer denials and pricing could negatively affect the revenue mix and pressure margins if reimbursement trends remain unfavorable.
GeneDx Holdings News
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $32.21 and its highest was $170.87 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $1.17B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is Aug 17, 2026 which is in 95 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on May 04, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.015 by -$0.265.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Undervalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is -0.19.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 29,688,026 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.015. Following the earnings report the stock price went down -49.198%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GeneDx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.25 (38.34% Upside)
$91.25 (38.34% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 179.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $57.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.91%
12-Months-Change
Fundamentals
Return on Equity
-27.50%
Trailing 12-Months
Asset Growth
13.41%
Trailing 12-Months
Company Description
GeneDx Holdings
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
WGS Company Deck
WGS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong operational momentum (34% volume growth, 27% exome/genome revenue growth, healthy ~69% adjusted gross margin, large proprietary dataset, new commercial products and expanded sales coverage) tempered by near-term execution and mix challenges (approximately $12M revenue shortfall in Q1 driven by lower blended ARR and $6.5M non-core misses), a significant Fabric impairment (~$31.3M), and a 12% reduction to prior full-year revenue expectations. Management laid out concrete remediation actions — tighter channel/revenue-cycle management, cost recalibration ($25M OpEx reduction), and focused commercial execution — and provided updated guidance that emphasizes line-of-sight growth and a pathway back to adjusted profitability in 2026, with further ARR improvement expected over multiple quarters as payer coverage and collections improve.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$91.25
▲(38.34% Upside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
42.24% Insiders
24.60% Mutual Funds
17.89% Other Institutional Investors
2.11% Public Companies and
Individual Investors